JP2020517294A5 - - Google Patents

Download PDF

Info

Publication number
JP2020517294A5
JP2020517294A5 JP2019558615A JP2019558615A JP2020517294A5 JP 2020517294 A5 JP2020517294 A5 JP 2020517294A5 JP 2019558615 A JP2019558615 A JP 2019558615A JP 2019558615 A JP2019558615 A JP 2019558615A JP 2020517294 A5 JP2020517294 A5 JP 2020517294A5
Authority
JP
Japan
Prior art keywords
gpc3
amino acid
seq
acid sequence
construct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019558615A
Other languages
English (en)
Japanese (ja)
Other versions
JP7295030B2 (ja
JP2020517294A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/029221 external-priority patent/WO2018200586A1/en
Publication of JP2020517294A publication Critical patent/JP2020517294A/ja
Publication of JP2020517294A5 publication Critical patent/JP2020517294A5/ja
Priority to JP2023094432A priority Critical patent/JP2023123540A/ja
Application granted granted Critical
Publication of JP7295030B2 publication Critical patent/JP7295030B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019558615A 2017-04-26 2018-04-24 グリピカン3を特異的に認識するコンストラクト及びその使用 Active JP7295030B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023094432A JP2023123540A (ja) 2017-04-26 2023-06-07 グリピカン3を特異的に認識するコンストラクト及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762490586P 2017-04-26 2017-04-26
US62/490,586 2017-04-26
PCT/US2018/029221 WO2018200586A1 (en) 2017-04-26 2018-04-24 Constructs specifically recognizing glypican 3 and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023094432A Division JP2023123540A (ja) 2017-04-26 2023-06-07 グリピカン3を特異的に認識するコンストラクト及びその使用

Publications (3)

Publication Number Publication Date
JP2020517294A JP2020517294A (ja) 2020-06-18
JP2020517294A5 true JP2020517294A5 (https=) 2021-06-10
JP7295030B2 JP7295030B2 (ja) 2023-06-20

Family

ID=63920003

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019558615A Active JP7295030B2 (ja) 2017-04-26 2018-04-24 グリピカン3を特異的に認識するコンストラクト及びその使用
JP2023094432A Pending JP2023123540A (ja) 2017-04-26 2023-06-07 グリピカン3を特異的に認識するコンストラクト及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023094432A Pending JP2023123540A (ja) 2017-04-26 2023-06-07 グリピカン3を特異的に認識するコンストラクト及びその使用

Country Status (15)

Country Link
US (2) US11447564B2 (https=)
EP (1) EP3615574A4 (https=)
JP (2) JP7295030B2 (https=)
KR (2) KR102663596B1 (https=)
CN (1) CN110741019B (https=)
AU (1) AU2018258049B2 (https=)
CA (1) CA3059820A1 (https=)
IL (2) IL319308A (https=)
MX (2) MX420947B (https=)
MY (1) MY201065A (https=)
PH (1) PH12019502412A1 (https=)
SG (2) SG11201909728XA (https=)
TW (1) TWI878207B (https=)
WO (1) WO2018200586A1 (https=)
ZA (1) ZA202000027B (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018004721A (es) 2015-10-23 2018-07-06 Eureka Therapeutics Inc Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas.
EP3615574A4 (en) 2017-04-26 2021-02-24 Eureka Therapeutics, Inc. SPECIFIC GLYPICAN 3 RECOGNIZING CONSTRUCTS AND THEIR USE
JP7538601B2 (ja) 2017-04-26 2024-08-22 ユーリカ セラピューティックス, インコーポレイテッド キメラ活性化受容体及びキメラ刺激受容体を発現する細胞並びにその使用
CA3102641A1 (en) 2018-06-22 2019-12-26 Kite Pharma, Inc. Chimeric transmembrane proteins and uses thereof
SG11202103234RA (en) * 2018-10-01 2021-04-29 Adicet Bio Inc COMPOSITIONS AND METHODS REGARDING ENGINEERED AND NON-ENGINEERED γδ -T CELLS FOR TREATMENT OF SOLID TUMORS
US10815308B2 (en) * 2018-12-21 2020-10-27 Kymab Limited FIXaxFX bispecific antibody with common light chain
CN113490689B (zh) * 2019-02-01 2024-06-04 恺兴生命科技(上海)有限公司 Tcr融合蛋白及表达tcr融合蛋白的细胞
EP3965897A4 (en) * 2019-05-07 2023-01-04 The Board of Trustees of the Leland Stanford Junior University CHEMERA ANTIGEN RECEPTORS TARGETING GLYPICAN-2
CN114391021B (zh) 2019-06-21 2026-01-16 凯德药业股份有限公司 TGF-β受体和使用方法
WO2021105989A1 (en) * 2019-11-26 2021-06-03 Ramot At Tel-Aviv University Ltd. Chimeric antigen receptor to carbohydrate antigens
WO2021126672A1 (en) * 2019-12-20 2021-06-24 Medimmune, Llc Compositions and methods of treating cancer with chimeric antigen receptors targeting glypican 3
MX2022009827A (es) * 2020-02-14 2022-09-05 Univ Leland Stanford Junior Receptores de antigenos quimericos con activacion de cd2.
CA3170023A1 (en) * 2020-02-27 2021-09-02 Nanjing Legend Biotech Co., Ltd. Antibodies and chimeric antigen receptors targeting glypican-3 (gpc3) and methods of use thereof
WO2021186395A1 (en) * 2020-03-18 2021-09-23 Eutilex Co., Ltd. Gpc3 car- t cells secreting il-18 and methods of making and using the same
MX2022013920A (es) * 2020-05-07 2022-11-30 Phanes Therapeutics Inc Anticuerpos anti-antigeno asociado con tumor y usos de los mismos.
TW202216788A (zh) * 2020-06-26 2022-05-01 日商協和麒麟股份有限公司 與GPC3及TfR結合之雙特異性抗體
JP2024513264A (ja) * 2021-04-05 2024-03-22 サイトヴィア セラピューティクス, エルエルシー Nkp46及びgpc3を標的とする二重特異性抗体、並びにその使用方法
AU2022260298A1 (en) * 2021-04-23 2023-11-02 Shanghai Henlius Biotech, Inc. Anti-gpc3 antibodies, multispecific antibodies and methods of use
CN113203780B (zh) * 2021-05-13 2022-05-31 桂林电子科技大学 一种非诊断目的无标记适配体传感器检测gpc3的方法
CN113238040B (zh) * 2021-05-18 2022-05-31 桂林电子科技大学 一种非诊断目的基于纳米复合材料的laps传感器检测gpc3方法
EP4341294A1 (en) * 2021-05-21 2024-03-27 BeiGene Switzerland GmbH Anti-gpc3 and anti-cd137 multispecific antibodies and methods of use
WO2022261061A1 (en) * 2021-06-08 2022-12-15 Kite Pharma, Inc. Gpc3 binding molecules
CN118488970A (zh) * 2021-10-15 2024-08-13 乐普创一生物科技(上海)有限公司 抗磷脂酰肌醇蛋白聚糖3抗体
US20250281538A1 (en) * 2022-05-02 2025-09-11 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Compositions targeting gpc2 and gpc3 and their use for treating solid tumors
WO2023249071A1 (ja) * 2022-06-24 2023-12-28 国立研究開発法人国立がん研究センター T細胞受容体
TW202413646A (zh) * 2022-07-22 2024-04-01 美商萊爾免疫藥物股份有限公司 免疫細胞療法
IL320949A (en) * 2022-11-21 2025-07-01 Beigene Switzerland Gmbh Antibodies against CD137 and methods of using them
WO2025159562A1 (ko) * 2024-01-24 2025-07-31 국립암센터 Gpc3에 특이적으로 결합하는 신규 항체 및 이의 용도

Family Cites Families (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US4994560A (en) 1987-06-24 1991-02-19 The Dow Chemical Company Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies
US5489425A (en) 1987-06-24 1996-02-06 The Dow Chemical Company Functionalized polyamine chelants
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
DE3850542T2 (de) 1987-09-23 1994-11-24 Bristol Myers Squibb Co Antikörper-Heterokonjugate zur Töting von HIV-infizierten Zellen.
US5756065A (en) 1988-06-24 1998-05-26 The Dow Chemical Company Macrocyclic tetraazacyclododecane conjugates and their use as diagnostic and therapeutic agents
ZA894792B (en) 1988-06-24 1991-04-24 Dow Chemical Co Macrocyclic bifunctional chelants,complexes thereof and their antibody conjugates
CA1341373C (en) 1988-06-24 2002-07-02 Roberta C. Cheng Macrocyclic bifunctional chelants, complexes thereof and their antibody conjugates
US5274119A (en) 1988-07-01 1993-12-28 The Dow Chemical Company Vicinal diols
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5696239A (en) 1988-10-31 1997-12-09 The Dow Chemical Company Conjugates possessing ortho ligating functionality and complexes thereof
US5342604A (en) 1988-10-31 1994-08-30 The Dow Chemical Company Complexes possessing ortho ligating functionality
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5808003A (en) 1989-05-26 1998-09-15 Perimmune Holdings, Inc. Polyaminocarboxylate chelators
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
US5428139A (en) 1991-12-10 1995-06-27 The Dow Chemical Company Bicyclopolyazamacrocyclophosphonic acid complexes for use as radiopharmaceuticals
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
US5505931A (en) 1993-03-04 1996-04-09 The Dow Chemical Company Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
ES2434840T3 (es) 1995-07-27 2013-12-17 Genentech, Inc. Formulación de proteína liofilizada isotónica estable
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
CA2635352C (en) 1997-06-13 2012-09-11 Genentech, Inc. Stabilized antibody formulation
ES2244066T3 (es) 1997-06-24 2005-12-01 Genentech, Inc. Procedimiento y composiciones de glicoproteinas galactosiladas.
AU759779B2 (en) 1997-10-31 2003-05-01 Genentech Inc. Methods and compositions comprising glycoprotein glycoforms
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
US7112324B1 (en) 1998-04-21 2006-09-26 Micromet Ag CD 19×CD3 specific polypeptides and uses thereof
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
HK1047109A1 (zh) 1999-10-15 2003-02-07 University Of Massachusetts 作为指定基因干预工具的rna干预轨迹基因
EP1229125A4 (en) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING A POLYPEPTIDE
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
JP2003516344A (ja) 1999-12-13 2003-05-13 エピミューン, インコーポレイテッド Hlaクラスia2腫瘍関連抗原ペプチドおよびワクチン組成物
EP1240319A1 (en) 1999-12-15 2002-09-18 Genentech, Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
KR20030032922A (ko) 2000-02-24 2003-04-26 싸이트 테라피스 인코포레이티드 세포의 동시 자극 및 농축
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
AU2001275474A1 (en) 2000-06-12 2001-12-24 Akkadix Corporation Materials and methods for the control of nematodes
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CA2953239A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kirin Co., Ltd. Antibody composition-producing cell
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
ATE410680T1 (de) 2001-05-26 2008-10-15 One Cell Systems Inc Sekretion von proteinen durch verkapselte zellen
NZ571596A (en) 2001-08-03 2010-11-26 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
WO2004022597A1 (ja) * 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha Gpc3の血中可溶化n端ペプチドに対する抗体
ATE503829T1 (de) 2002-04-09 2011-04-15 Kyowa Hakko Kirin Co Ltd Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING ANTIBODY COMPOSITION
BR0309145A (pt) 2002-04-09 2005-02-01 Kyowa Hakko Kogyo Kk Células das quais o genoma é modificado
EP1500400A4 (en) 2002-04-09 2006-10-11 Kyowa Hakko Kogyo Kk MEDICAMENT WITH ANTIBODY COMPOSITION
CA2481658A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to fcy receptor iiia
CA2481925A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for patients having human fc.gamma.riiia
CA2488441C (en) 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
TWI335821B (en) 2002-12-16 2011-01-11 Genentech Inc Immunoglobulin variants and uses thereof
WO2004065416A2 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
US7393531B2 (en) * 2003-01-21 2008-07-01 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
JPWO2005035586A1 (ja) 2003-10-08 2007-11-22 協和醗酵工業株式会社 融合蛋白質組成物
JPWO2005035778A1 (ja) 2003-10-09 2006-12-21 協和醗酵工業株式会社 α1,6−フコシルトランスフェラーゼの機能を抑制するRNAを用いた抗体組成物の製造法
US9296820B2 (en) 2003-11-05 2016-03-29 Roche Glycart Ag Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
WO2005053742A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
PT1737891E (pt) 2004-04-13 2013-04-16 Hoffmann La Roche Anticorpos anti p-selectina
SI1674111T1 (sl) * 2004-07-09 2011-02-28 Chugai Pharmaceutical Co Ltd Protitelo proti glipikanu 3
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ox40l抗體
DK1791565T3 (en) 2004-09-23 2016-08-01 Genentech Inc Cysteingensplejsede antibodies and conjugates
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
ES2577292T3 (es) 2005-11-07 2016-07-14 Genentech, Inc. Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
EP1973951A2 (en) 2005-12-02 2008-10-01 Genentech, Inc. Binding polypeptides with restricted diversity sequences
TW200812616A (en) 2006-05-09 2008-03-16 Genentech Inc Binding polypeptides with optimized scaffolds
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
ME02345B (me) 2007-07-17 2016-08-31 Squibb & Sons Llc MONOKLONSKA ANTlTELA PROTIV GLIPIKANA-3
EP2225277A4 (en) 2007-11-27 2012-03-14 Viventia Biotech Inc ANTIBODIES TO A CANCER-ASSOCIATED EPITOPE OF THE VARIANT NFKBIB AND APPLICATIONS THEREOF
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング(electrostaticsteering)効果を用いた抗体Fcヘテロ二量体分子を作製するための方法
KR101860963B1 (ko) 2010-04-23 2018-05-24 제넨테크, 인크. 이종다량체 단백질의 생산
EP2699603B1 (en) * 2011-04-19 2016-03-02 The United States of America As Represented by the Secretary Department of Health and Human Services Human monoclonal antibodies specific for glypican-3 and use thereof
RU2654567C2 (ru) 2011-10-11 2018-05-21 Дженентек, Инк. Улучшенная сборка биспецифических антител
WO2013070468A1 (en) * 2011-11-08 2013-05-16 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
SG11201407972RA (en) * 2012-06-01 2015-01-29 Us Health High-affinity monoclonal antibodies to glypican-3 and use thereof
WO2014138314A1 (en) 2013-03-05 2014-09-12 Baylor College Of Medicine Oncolytic virus
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
CN104140974B (zh) 2013-05-08 2017-09-29 科济生物医药(上海)有限公司 编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞
US20170335281A1 (en) * 2014-03-15 2017-11-23 Novartis Ag Treatment of cancer using chimeric antigen receptor
EP2944652A1 (en) * 2014-05-13 2015-11-18 Technische Universität München Glypican-3-specific T-cell receptors and their uses for immunotherapy of hepatocellular carcinoma
WO2015179658A2 (en) * 2014-05-22 2015-11-26 Genentech, Inc. Anti-gpc3 antibodies and immunoconjugates
US10093746B2 (en) * 2014-09-04 2018-10-09 The Trustees Of The University Of Pennsylvania Glypican-3 antibody and uses thereof
JP2017529851A (ja) * 2014-09-26 2017-10-12 ベイラー カレッジ オブ メディスンBaylor College Of Medicine 養子免疫療法のためのグリピカン−3特異的キメラ抗原レセプター
WO2016161390A1 (en) * 2015-04-03 2016-10-06 Eureka Therapeutics, Inc. Constructs targeting afp peptide/mhc complexes and uses thereof
PL3298033T5 (pl) 2015-05-18 2023-10-30 TCR2 Therapeutics Inc. Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych
MX2018004721A (es) 2015-10-23 2018-07-06 Eureka Therapeutics Inc Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas.
CA3032498A1 (en) 2016-08-02 2018-02-08 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
WO2018067993A1 (en) 2016-10-07 2018-04-12 TCR2 Therapeutics Inc. Compositions and methods for t-cell receptors reprogramming using fusion proteins
JP7291396B2 (ja) 2016-11-22 2023-06-15 ティーシーアール2 セラピューティクス インク. 融合タンパク質を用いたtcrの再プログラミングのための組成物及び方法
JP2020513754A (ja) 2016-12-21 2020-05-21 ティーシーアール2 セラピューティクス インク. がん治療用に操作されたt細胞
US20190359678A1 (en) 2017-02-09 2019-11-28 The Regents Of The University Of California Chimeric t cell antigen receptors and methods of use thereof
EP3615574A4 (en) 2017-04-26 2021-02-24 Eureka Therapeutics, Inc. SPECIFIC GLYPICAN 3 RECOGNIZING CONSTRUCTS AND THEIR USE
WO2018232020A1 (en) 2017-06-13 2018-12-20 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
KR102061677B1 (ko) 2018-08-23 2020-02-11 주식회사 나노테크 텅스텐과 티타늄 복합 탄화물 분말의 제조 방법

Similar Documents

Publication Publication Date Title
JP2020517294A5 (https=)
JP7748933B2 (ja) 抗dll3キメラ抗原受容体及びその使用
JP2023518134A5 (https=)
RU2558301C2 (ru) Полипептиды для связывания с "рецептором конечных продуктов гликирования", а также их композиции и способы, в которых они принимают участие
JP6557657B2 (ja) 分子
JP2018512145A5 (https=)
AU2016262662A1 (en) Antibodies that bind csf1r
JP2022542543A5 (https=)
RU2018102526A (ru) Конструкции, направленные на комплексы пептида ny-eso-1/мнс, и их применение
JP2024023228A5 (https=)
CN111378044B (zh) 抗体融合蛋白、制备方法及其应用
CN115066274A (zh) 三价结合分子
RU2018104703A (ru) Опухолеспецифичное антитело против egfr и его применение
JP2021528382A (ja) 免疫エフェクター細胞を腫瘍細胞へ誘引する方法及び手段
CN104628866A (zh) 一种靶向vegfr2的抗体融合蛋白的制备及其用途
CN115279792A (zh) 对bcma特异的抗体及嵌合抗原受体
AU2025200577A1 (en) BTNL3/8 targeting constructs for delivery of payloads to the gastrointestinal system
JP2024515919A5 (https=)
KR20240082403A (ko) 항-bcma 단일 도메인 항체 및 치료 작제물
TW202309083A (zh) 抗cldn4-抗cd137雙特異性抗體
US20210363265A1 (en) Multivalent receptor-clustering agonist antibody constructs
CN110938146B (zh) Tim-3单域抗体及其应用
CN120112555A (zh) 抗vista单克隆抗体及其用途
JP2024539079A5 (https=)
EP3014271A1 (en) Target antigen discovery, phenotypic screens and use thereof for identification of target cell specific target epitopes